SCHEMBL1716286

SCHEMBL1716286

N#CCc1ccccc1CON1C(=O)c2ccccc2C1=O

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.57
HTT P42858 1/20 0.57
KMT2A Q03164 5/20 0.50
MEN1 O00255 4/20 0.50
MAPT P10636 2/20 0.50
GAA P10253 3/20 0.49
ATM Q13315 1/20 0.44
CYP1A2 P05177 2/20 0.43
CYP2C9 P11712 1/20 0.43
HPGD P15428 2/20 0.42
RECQL P46063 1/20 0.39
PDE4A P27815 1/20 0.36
PDE4B Q07343 1/20 0.36
PDE4C Q08493 1/20 0.36
PDE4D Q08499 1/20 0.36
POLB P06746 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17161188 0.80 ALDH1A1 (0.60) ALDH1A1HTTKMT2AMEN1MAPT
SCHEMBL3374656 0.80 ALDH1A1 (0.60) ALDH1A1HTTKMT2AMEN1MAPT
SCHEMBL3755047 0.78 GAA (0.56) ALDH1A1HTTKMT2AMEN1MAPT
SCHEMBL21045989 0.77 MEN1 (0.61) ALDH1A1HTTKMT2AMEN1MAPT
SCHEMBL8914413 0.77 KMT2A (0.61) ALDH1A1HTTKMT2AMEN1MAPT
SCHEMBL5558965 0.74 ALDH1A1 (0.57) ALDH1A1HTTKMT2AMEN1MAPT
SCHEMBL21045990 0.74 ALDH1A1 (0.57) ALDH1A1HTTKMT2AMEN1MAPT
SCHEMBL5528949 0.73 ALDH1A1 (1.00) ALDH1A1HTTKMT2AMEN1MAPT
SCHEMBL31236761 0.73 ALDH1A1 (1.00) ALDH1A1HTTKMT2AMEN1MAPT
SCHEMBL5526032 0.73 KMT2A (0.65) ALDH1A1HTTKMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8034811-B2 Hydroxamic acid esters and pharmaceutical use thereof LEO PHARMA A/S (DK) 2011-10-11 US disclosed
EP-1697312-B1 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF LEO PHARMA AS (DK) 2011-07-20 EP disclosed
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof LEO PHARMA A/S (DK) 2007-10-18 US disclosed
EP-1697312-A2 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF Leo Pharma A/S (DK) 2006-09-06 EP disclosed
WO-2005054179-A2 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF LEO PHARMA A/S (DK) 2005-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof F9, F12, HDAC9 ALDH1A1 804/4885HTT 2013/4885KMT2A 1452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.